Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
100%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
4
67%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (33.3%)
Phase 34 (66.7%)

Trials by Status

recruiting117%
completed233%
terminated117%
unknown233%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_3

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

NCT06889688
completedphase_3

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622
completedphase_2

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

NCT04680988
terminatedphase_3

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01849874
unknownphase_3

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

NCT04296370
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06889688Phase 3

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Recruiting
NCT02000622Phase 3

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Completed
NCT04680988Phase 2

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Completed
NCT01849874Phase 3

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Terminated
NCT04296370Phase 3

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Unknown
NCT02649101Phase 2

Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6